安润医药科技

Suzhou Anrun Pharmaceutical Technology is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs. Based in Suzhou's BioBAY, the company focuses on challenging targets, particularly protein-protein interactions (PPIs) that have historically been considered undruggable. Anrun utilizes a proprietary technology platform that integrates fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) to accelerate the development of high-affinity leads. Its lead clinical program, AR-001, is a small molecule inhibitor of the MDM2-p53 interaction designed to treat solid tumors and hematological malignancies. Beyond its lead asset, the company maintains a growing pipeline of early-stage programs targeting oncology and inflammatory pathways. Anrun Pharma is led by a team of industry veterans with extensive experience in global pharmaceutical research and development.